SHEL.UK

2,920

+1.99%↑

BP

469.3

+2.09%↑

SHEL.UK

2,920

+1.99%↑

BP

469.3

+2.09%↑

SHEL.UK

2,920

+1.99%↑

BP

469.3

+2.09%↑

SHEL.UK

2,920

+1.99%↑

BP

469.3

+2.09%↑

SHEL.UK

2,920

+1.99%↑

BP

469.3

+2.09%↑

Search

Smith & Nephew PLC

Gesloten

1,333 0.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1313.5

Max

1338

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

32.354

25.238

EPS

0.429

Dividendrendement

2.89

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+12.5% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.89%

4.00%

Volgende Winsten

2 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

11B

Vorige openingsprijs

1332.17

Vorige sluitingsprijs

1333

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 feb 2026, 23:44 UTC

Populaire aandelen

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 feb 2026, 23:20 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 feb 2026, 22:57 UTC

Winsten

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 21:59 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 feb 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 feb 2026, 23:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 feb 2026, 23:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 feb 2026, 23:45 UTC

Marktinformatie

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 feb 2026, 23:19 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 23:15 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:58 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 feb 2026, 22:58 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 feb 2026, 22:57 UTC

Acquisities, Fusies, Overnames

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 feb 2026, 22:50 UTC

Acquisities, Fusies, Overnames

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 feb 2026, 22:44 UTC

Winsten

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:42 UTC

Winsten

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 22:36 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 feb 2026, 22:36 UTC

Winsten

Santos Final Dividend 10.3 U.S. Cents/Security

17 feb 2026, 22:36 UTC

Winsten

Santos FY Underlying Profit US$898 Million, Down 25%

17 feb 2026, 22:35 UTC

Winsten

Santos FY Revenue US$4.94 Billion, Down 8%

17 feb 2026, 22:35 UTC

Winsten

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 feb 2026, 22:35 UTC

Acquisities, Fusies, Overnames

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 feb 2026, 22:34 UTC

Winsten

Santos FY Net Profit US$818 Billion, Down 33%

17 feb 2026, 22:02 UTC

Acquisities, Fusies, Overnames

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 feb 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 feb 2026, 21:49 UTC

Acquisities, Fusies, Overnames

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

12.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,490.57 GBX  12.5%

Hoogste 1,650 GBX

Laagste 1,290 GBX

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat